Methadone vs Buprenorphine: A Deep Dive into Opioid Treatment Options
Episode Overview
Methadone promotes better retention in treatment compared to buprenorphine. Mortality rates are low and similar for both medications. Engaging non-abstinent patients is crucial for effective treatment. The Modernizing Opioid Treatment Access Act aims to expand access to methadone. Supporting frontline staff is essential in addiction care.
Retention and engagement should be the primary desired outcomes rather than drug abstinence.
In this episode of the Addiction Medicine Journal Club, Dr. John Keenan and Dr. Sonya Del Tredici dive into a comparison between methadone and buprenorphine for treating opioid use disorder. They discuss a recent study published in JAMA, which looks at treatment retention and mortality rates among patients using these medications. The conversation covers the nuances of each treatment option, including accessibility, patient preferences, and the broader implications for addiction medicine.
The hosts also touch on the Modernizing Opioid Treatment Access Act and the importance of engaging non-abstinent patients in treatment. They highlight the evolving views within the recovery community and the ongoing debate about medication-assisted treatment. The episode is packed with insights, practical advice, and real-world examples that can benefit both healthcare professionals and those affected by opioid use disorder. Don't miss out on this informative and engaging discussion that could change how you view addiction treatment.